Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
01 1Wavelength Enterprises Ltd
02 1Patheon Italia S.p.A.
01 1REMIMAZOLAM BESYLATE
02 1remimazolam besylate
01 1France
02 1U.S.A
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
NDC Package Code : 58175-0648
Start Marketing Date : 2022-08-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 68225-120
Start Marketing Date : 2020-07-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (2.5mg/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
A Remimazolam manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Remimazolam, including repackagers and relabelers. The FDA regulates Remimazolam manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Remimazolam API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Remimazolam manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Remimazolam supplier is an individual or a company that provides Remimazolam active pharmaceutical ingredient (API) or Remimazolam finished formulations upon request. The Remimazolam suppliers may include Remimazolam API manufacturers, exporters, distributors and traders.
click here to find a list of Remimazolam suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Remimazolam as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Remimazolam API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Remimazolam as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Remimazolam and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Remimazolam NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Remimazolam suppliers with NDC on PharmaCompass.
LOOKING FOR A SUPPLIER?
